Skip to Main Content

Paper Details

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Cancer Res
42
2020
EGFR, EGFR-, EGFR-mutant osimertinib-resistant NSCLC models, EGFRi, IACS-13909, MAPK, NSCLC, Osimertinib, RTK, RTK-activated cancers, RTKs, SHP2, Src homology 2 domain-containing phosphatase, non-small cell lung cancer, osimertinib, patient, receptor tyrosine kinases, tumor, tumor cell, tumors, tyrosine, tyrosine kinase
Author NameAffiliation
Christopher A BristowThe University of Texas MD Anderson Cancer Center
Christopher A BristowThe University of Texas MD Anderson Cancer Center
Justin K HuangThe University of Texas MD Anderson Cancer Center
Jeffrey J KovacsThe University of Texas MD Anderson Cancer Center
Sahil SethThe University of Texas MD Anderson Cancer Center
Sahil SethThe University of Texas MD Anderson Cancer Center
Timothy P HeffernanThe University of Texas MD Anderson Cancer Center
  • 1 - 7

Datasets

Release 1.2